The population was 86% White, 3% Black, 0.4% Hispanic, and 10% of other ethnicities, and included patients with ED

5.8 Hepatic Impairment

Timing of sexual activity was not restricted relative to when patients took Cialis. Results in General ED Population — The primary US efficacy and safety trial included a total of 287 patients, with a mean age of 59 years (range 25 to 82 years). The population was 86% White, 6% Black, 6% Hispanic, and 2% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Most (>96%) patients reported ED of at least 1-year duration. The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56 years (range 21 to 78 years). of various severities, etiologies (organic, psychogenic, mixed), and with multiple

Product Dosage Quantity + Bonus Price
Cialis Generic10mg10 Pills31.41€ 29.91€
Cialis Generic2.5mg180 + 10 Pills154.86€ 147.49€
Cialis Generic20mg20 Pills54.72€ 52.11€
Cialis Black80mg90 + 6 Pills207.88€ 197.98€
Cialis Generic60mg10 Pills41.22€ 39.26€
Cialis Professional20mg120 + 4 Pills291.68€ 277.79€
Cialis Original20mg76 + 4 Pills319.19€ 303.99€
Cialis Professional40mg180 + 4 Pills618.23€ 588.79€
Cialis Generic10mg30 + 4 Pills63.32€ 60.30€
Cialis Generic20mg90 + 6 Pills154.71€ 147.34€
Cialis Professional40mg30 Pills148.94€ 141.85€

co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease.

  • Cialis introduction changed the landscape of erectile dysfunction treatment.
  • It offered an alternative with longer duration than prior PDE5 inhibitors.
  • Market acceptance was driven by favorable patient and clinician feedback.
  • Some men prefer Cialis due to reduced planning for sexual activity.
  • The drug's patent provided Lilly a commercial advantage for years.
  • Extensive advertising targeted both physicians and consumers.
  • Patient support groups often discuss experiences with Cialis.
  • Alternative ED treatments include injections, vacuum pumps, and surgery.
  • Cialis fits a broad spectrum of ED severity levels.
  • Diabetes, hypertension, and heart disease are common conditions with Cialis use.
  • Lilly continues efforts to educate about safe sexual health practices.
  • Ongoing clinical trials explore broader uses of tadalafil.

Ninety-three percent of patients reported ED of at least 1-year duration.

Similar questions

Patients were free to choose the time interval between dose administration and the time of sexual attempts. Food and alcohol intake were not restricted. Several assessment tools were used to evaluate the effect of CIALIS on erectile function. The 3 primary outcome measures were the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) and Questions 2 and 3 from Sexual Encounter Profile (SEP). The IIEF is a 4-week recall questionnaire that was administered at the end of a treatment-free baseline period and subsequently at follow-up visits after randomization.

1 billion products

The IIEF EF domain has a 30-point total score, where higher scores reflect better erectile function. SEP is a diary in which patients recorded each sexual attempt made throughout the study. SEP Question 2 asks, “Were you able to insert your penis into the partner's vagina?” SEP Question 3 asks, “Did your erection last long enough for you to have successful intercourse?” The overall percentage of successful attempts to insert the penis into the vagina (SEP2) and to maintain the erection for successful intercourse (SEP3) is derived for each patient. Results in ED Population in US Trials — The 2 primary US efficacy and safety trials included a total of 402 men with erectile dysfunction, with a mean age of 59 years (range 27 to 87 years). The population was 78% White, 14% Black, 7% Hispanic, and 1% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease.

4.2 Hypersensitivity Reactions

Most (>90%) white cialis pill patients reported ED of at least 1-year duration. Study A was conducted primarily in academic centers. Study B was conducted primarily in community-based urology practices. In each of these 2 trials, CIALIS 20 mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (see Table 11). The treatment effect of CIALIS did not diminish over time. In each of these trials, conducted without regard to the timing of dose and sexual intercourse, CIALIS demonstrated clinically meaningful and statistically significant improvement

  • Cialis tablets come with different packaging, including blister packs and bottles.
  • Eli Lilly provides comprehensive patient information leaflets with Cialis.
  • Cialis is sometimes prescribed off-label for Raynaud’s phenomenon.
  • The medication has a bioavailability of about 80%.
  • Food intake has minimal impact on Cialis absorption.
  • Cialis is metabolized primarily by the liver enzyme CYP3A4.
  • Dose adjustments might be necessary for patients with kidney impairment.
  • Cialis’s half-life is approximately 17.5 hours, contributing to long effect.
  • Lilly has faced generic competition for Cialis in many markets.
  • The drug’s patent expiration allowed entry of tadalafil generics.
  • Cialis is included in some clinical guidelines for ED management.
  • Monitoring for rare but serious side effects is part of patient care.

in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 17).

5.5 Sudden Hearing Loss

A successful erection was defined as at least 1 erection in 4 attempts that led to successful intercourse. At or prior to 30 minutes, 35% (26/74), 38% (28/74), and 52% (39/75) of patients in the placebo, cialis tablet price 10-, and 20-mg groups, respectively, reported successful erections as defined above. Two studies were conducted to assess the efficacy of CIALIS at a given timepoint after dosing, specifically at 24 hours and at 36 hours after dosing. In the first of these studies, 348 patients with ED were randomized to placebo or CIALIS 20 mg. Patients were encouraged to make 4 total attempts at intercourse; 2 attempts were to occur at 24 hours after dosing and 2 completely separate attempts were to occur at 36 hours after dosing.

2.2 CIALIS for Once Daily Use for Erectile Dysfunction

The results demonstrated a difference between the placebo group and the CIALIS group at each of the pre-specified timepoints. At the 24-hour timepoint, (more specifically, 22 to 26 hours), 53/144 (37%) patients reported at least 1 successful intercourse in the placebo group versus 84/138 (61%) in the CIALIS 20-mg group. At the 36-hour timepoint (more specifically, 33 to 39 hours), 49/133 (37%) of patients reported at least 1 successful intercourse in the placebo group versus 88/137 (64%) in the CIALIS 20-mg group. In the second of these studies, a total of 483 patients were evenly randomized to 1 of 6 groups: 3 different dosing groups (placebo, CIALIS 10, or 20 mg) that were instructed to attempt intercourse at 2 different times (24 and 36 hours post-dosing). Patients were encouraged to make 4 separate attempts at their assigned dose and assigned timepoint.

17.5 Potential for Drug Interactions When Taking CIALIS for Once Daily Use

In this study, the results demonstrated a statistically significant difference between the placebo group and the CIALIS groups at each of the pre-specified timepoints. At the 24-hour timepoint, the mean, per patient percentage of attempts resulting in successful intercourse were 42, 56, and 67% for the placebo, CIALIS 10-, and 20-mg groups, respectively. At the 36-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 33, 56, and 62% for placebo, CIALIS 10-, and 20-mg groups, respectively. The efficacy and safety of CIALIS for once daily use in the treatment of erectile dysfunction has been evaluated in 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853 patients. CIALIS, when taken once daily, was shown to be effective in order cialis online without a prescription improving erectile function in men with erectile dysfunction (ED). When taken as directed, CIALIS was effective at improving erectile function. In the 6 month double-blind study, the treatment effect of CIALIS did not diminish over time.

Attribute Description Notes
Generic Name Tadalafil Main active ingredient
Brand Name Cialis (by Lilly) Commercial name
Dosage Forms Tablets, oral Available forms
Typical Dose 5 mg, 10 mg, 20 mg Varies per prescription
Onset of Action 30-60 minutes Time to effect
Duration of Effect Up to 36 hours Pharmacological window

Efficacy Results in ED Patients with Diabetes Mellitus — CIALIS for once daily use was shown to be effective in treating ED in patients with diabetes mellitus.

Stores to help you save

CIALIS was studied in the general ED population in 2 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12- and 24-weeks duration, respectively. One of these studies was conducted in the United States and one was conducted in centers outside the US. An additional efficacy and safety study was performed in ED patients with diabetes mellitus. CIALIS was taken once daily at doses ranging from 2.5 to 10 mg. Food and alcohol intake were not restricted. Patients with diabetes were included in both studies in the general ED population (N=79).

Dosage Recommended Patient Group Notes
10 mg daily Adults with ED, as needed 30 minutes before activity
5 mg daily Men with prostate symptoms Once daily, at same time each day
20 mg as needed Occasional use, ED episodes Max dose per 24 hours
Adjustments Liver or kidney impairment Lower doses recommended

A third randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design trial included only ED patients with type 1 or type 2 diabetes (N=298).

2.5 Use with Food

Results in General ED Population in Trials Outside the US — The 5 primary efficacy and safety studies conducted in the general ED population outside the US included 1112 patients, with a mean age of 59 years (range 21 to 82 years). The population was 76% White, 1% Black, 3% Hispanic, and 20% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Most (90%) patients reported ED of at least 1-year duration. In these 5 trials, CIALIS 5, 10, and 20 mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (see Tables 12, 13 and 14). In addition, there were improvements in EF domain scores, success rates based upon SEP Questions 2 and 3, and patient-reported improvement in erections across patients with ED of all degrees of disease severity while taking CIALIS, compared to patients on placebo.

17.11 Recommended Administration

Therefore, in all 7 primary efficacy and safety studies, CIALIS showed statistically significant improvement in patients' ability to achieve an erection sufficient for vaginal penetration and to maintain the erection long enough for successful intercourse, as measured by the IIEF questionnaire and by SEP diaries. Efficacy Results in ED Patients with Diabetes Mellitus — CIALIS was shown to be effective in treating ED in patients with diabetes mellitus. Patients with diabetes were included in all 7 primary efficacy studies in the general ED population (N=235) and in one study that specifically assessed CIALIS in ED patients with type 1 or type 2 diabetes (N=216). In this randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial, CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 15). Efficacy Results in ED Patients following Radical Prostatectomy — CIALIS was shown to be effective in treating patients who developed ED following bilateral nerve-sparing radical prostatectomy.

Benign prostatic hyperplasia

In 1 randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial in this population (N=303), CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 16). Results in Studies to Determine the Optimal Use of CIALIS — Several studies were conducted with the objective of determining the optimal use of CIALIS in the treatment of ED. In one of these studies, the percentage of patients reporting successful erections within 30 minutes of dosing was determined. In this randomized, placebo-controlled, double-blinded trial, 223 patients were randomized to placebo, CIALIS 10, or 20 mg. Using a stopwatch, patients recorded the time following dosing at which a successful erection was obtained.